Sepsis Clinical Trial
Official title:
VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients
Verified date | October 2023 |
Source | Vivacelle Bio |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: 1. Male or female at least 18 years of age 2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection or an elevated procalcitonin of = 2 ng/ml. 3. Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market. 4. Sequential Organ Failure Assessment (SOFA) score >= 5. 5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria: - Lactate > 2 mmol/L - Mottled skin - Decreased capillary refill of nail beds or skin - Fever > 38.3°C, or 101°F - Hypothermia < 36°C core temperature (<96.8°F) - Heart rate > 90 - Tachypnea - Change in mental status - Significant edema or positive fluid balance (>20 mL/kg over 24 hours) - Hyperglycemia (>140 mg/dL) in someone without diabetes - White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature - forms) - Elevated C-reactive protein in serum (according to your lab's cutoffs) - Elevated procalcitonin in serum (= 2 ng/ml) - Arterial hypoxemia (PaO2/FiO2 < 300) - Acute drop in urine output (<0.5 ml/kg/hr for at least 2 hours despite fluid resuscitation, or about 30 ml/hour for a 70 kg person) - Creatinine increase > 0.5 mg/dL - INR > 1.5 or aPTT > 60 seconds - Absent bowel sounds (ileus) - High bilirubin (total bilirubin > 4 mg/dL Exclusion Criteria: 1. Patients with a ventricular assist device 2. Acute coronary syndrome 3. Pregnant 4. Bronchospasm 5. Mesenteric ischemia 6. Emergency surgery 7. Acute liver disease (Hepatitis B and C as examples) 8. Liver failure with a Model for End-Stage Liver Disease (MELD) score = 19 9. Hematologic or coagulation disorders including thrombocytopenia (platelet count <50,000) and associated with hemodynamically significant active bleeding. 10. Absolute neutrophil count of < 1000 mm3 11. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 and or septic shock 12. Patients with a known allergy to soybeans or eggs 13. Patient is hypervolemic as assessed by CVP, ultrasound, Swan Ganz catheter, Flo-Trac, esophageal doppler, bioimpedance, ECHO, Partial carbon dioxide rebreathing (NICO), lithium dilution (LIDCO) or other method published in a peer reviewed journal |
Country | Name | City | State |
---|---|---|---|
United States | UMD Shock Trauma | Baltimore | Maryland |
United States | Dignity Health | Chandler | Arizona |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Einstine Medical Center | East Norriton | Pennsylvania |
United States | Truman Medical Center | Kansas City | Missouri |
United States | Mount Sinai Hospital | New York | New York |
United States | Adventist Health Care | Silver Spring | Maryland |
United States | University of Arizona | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Vivacelle Bio |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint of this study is the proportion of patients in whom mean blood pressure increased by at least 10 mmHg with a mean blood pressure target of 60 - 65 mmHg. | The primary endpoint of this study is the proportion of patients in whom mean blood pressure increased by at least 10 mmHg with a mean blood pressure target of 60 - 65 mmHg. | 10 Months | |
Secondary | The secondary endpoint of this study is the proportion of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg | The secondary endpoint of this study is the proportion of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg | 10 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |